SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Astrana Health, Inc. (ASTH) trades at a trailing P/E of 59.8, forward P/E of 23.7. Trailing earnings yield is 1.67%, forward earnings yield 4.22%. PEG 0.14 (Peter Lynch undervalued ≤1.0). Graham Number is $10.80.
Criteria proven by this page:
- VALUE (66/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.14); analyst target implies upside (+12.7%).
- Forward P/E 23.7 (down from trailing 59.8) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.14 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 1.67% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 4.22% as earnings recover.
- Analyst consensus target $32.75 (+12.7% upside) — modest upside expected.
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
66/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ASTH
Valuation Multiples
P/E (TTM)59.8
Forward P/E23.7
PEG Ratio0.14
Forward PEG0.14
P/B Ratio1.73
P/S Ratio0.43
EV/EBITDA15.7
Per Share Data
EPS (TTM)$0.46
Forward EPS (Est.)$1.23
Book Value / Share$11.34
Revenue / Share$64.63
FCF / Share$2.18
Yields & Fair Value
Earnings Yield1.67%
Forward Earnings Yield4.22%
Dividend Yield0.00%
Graham Number$10.80
SharesGrow IV$42.41 (+45.9%)
Analyst Target$32.75 (+12.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
0.0 |
0.00 |
0.00 |
0.00 |
- |
| 2017 |
23.7 |
0.00 |
3.83 |
1.71 |
1.71% |
| 2018 |
60.3 |
-0.90 |
3.62 |
1.26 |
2.72% |
| 2019 |
45.3 |
1.87 |
3.34 |
1.14 |
9.66% |
| 2020 |
-28.1 |
-0.18 |
2.02 |
1.80 |
7.69% |
| 2021 |
46.7 |
0.92 |
7.19 |
4.16 |
0.97% |
| 2022 |
29.5 |
-0.81 |
2.45 |
1.16 |
1.05% |
| 2023 |
29.8 |
0.99 |
2.95 |
1.31 |
3.43% |
| 2024 |
34.8 |
-1.16 |
2.11 |
0.74 |
0.27% |
| 2025 |
54.1 |
-1.09 |
1.56 |
0.38 |
0.65% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-1.79 |
$44.05M |
$-9.34M |
-21.2% |
| 2017 |
$0.90 |
$357.75M |
$25.8M |
7.2% |
| 2018 |
$0.29 |
$519.91M |
$10.84M |
2.1% |
| 2019 |
$0.39 |
$560.62M |
$14.12M |
2.5% |
| 2020 |
$-0.63 |
$370.25M |
$-23.75M |
-6.4% |
| 2021 |
$1.52 |
$773.92M |
$68.92M |
8.9% |
| 2022 |
$0.99 |
$1.14B |
$45.17M |
3.9% |
| 2023 |
$1.29 |
$1.39B |
$60.72M |
4.4% |
| 2024 |
$0.89 |
$2.03B |
$43.15M |
2.1% |
| 2025 |
$0.46 |
$3.18B |
$22.49M |
0.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$1.23 |
$0.03 – $1.76 |
$3.99B |
$3.97B – $4B |
4 |
| 2027 |
$1.88 |
$0.80 – $2.96 |
$4.38B |
$4.03B – $4.74B |
4 |
| 2028 |
$2.21 |
$2.11 – $2.33 |
$4.64B |
$4.48B – $4.83B |
1 |
| 2029 |
$2.81 |
$2.68 – $2.96 |
$5.02B |
$4.84B – $5.22B |
1 |
| 2030 |
$3.40 |
$3.24 – $3.58 |
$5.41B |
$5.22B – $5.63B |
1 |
